HTL Biotechnology is a French biotech and a world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers (Hyaluronic acid, polynucleotides). Used by healthcare companies for the development of treatments in various cutting-edge therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology.
For over 30 years, HTL Biotechnology has been a driving force behind innovation in the sector, collaborating with research entities and biotech companies to address unmet medical needs (regenerative medicine, drug delivery, etc.) HTL Biotechnology recently reinforced its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc (HTL BII – New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) within a world-class scientific research center.
To meet growing global needs for biopolymers, the company has also subsidiaries in Asia and building in the United States, a neuromodulator production unit (HTL BMI – Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, research and development, as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide.
Our ambition is to consolidate our global leadership and create value for our customers with four priorities:
Premium positioning, by guaranteeing a high level of product quality and safety.
Innovation, by driving research in the biopolymers sector.
International expansion, by placing production and R&D at the service of new markets and customers.
Social responsibility, through which we aim to transform the biopolymer sector into a positive, sustainable force.
Social media group policy: https://htlbiotech.com/wp-content/uploads/2025/03/charte-reseaux-sociaux.pdf